Search Results
Bispecific antibodies in B-ALL; blinatumomab
Bispecific T-Cell Engagers (BiTEs) as Treatment of B-Cell Lymphoma
Blinatumomab demonstrates significant clinical activity in residual ALL
SWOG 1318: dasatinib plus blinatumomab in the treatment of older patients with B-ALL
Patrick Brown: Is Blinatumomab a New Standard of Care Young Patients With B-Cell ALL?
Antibodies in haemato-oncology
Updates on bispecific T cell engagers (BiTEs) for the treatment of acute lymphoblastic leukaemia
B-ALL patient selection for treatment with blinatumomab
Real-world outcomes of patients with R/R B-ALL treated with blinatumomab and inotuzumab ozogamicin
Genomic determinants of response to blinatumomab
Module 1 Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia
The importance of optimizing treatment of B-ALL at induction
